fig2
![Biomarkers in anderson-Fabry disease: what should we use in the clinical practice?](https://image.oaes.cc/e49d83c8-5d57-4f19-b6eb-2b86a21dc08e/rdodj3056.fig.2.jpg)
Figure 2. What biomarkers should we use in clinical practice? *not useful in female patients with late-onset phenotype; **characteristic pattern in FD; ***to predict treatment response; Lyso-Gb3: Globotriaosylsphingosine; TDI: tissue Doppler imaging; LGE: late gadolinium enhancement; eGFR: estimated GFR; MRI: magnetic resonance imaging.